Evidence map›Paper›PMID 41446785›Full record

ArticleFrontiers in pharmacology2025

Validation of diagnostic screening test for pharmacogenomic targets for thiopurine drugs in indian pediatric acute lymphoblastic leukemia patients.

Gratial Theres Joseph, Sandeep Kumar Swain, Tejas Somwanshi, Aarishi Singh, Manpreet Kaur, Raj Kamal, Himanshu Dhanda, Prashant Kumar, Upasana Kaushik, Baseer Noor and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gratial Theres Joseph *ICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Sandeep Kumar Swain *ICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Tejas SomwanshiICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Aarishi SinghICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Manpreet KaurICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Raj KamalICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Himanshu DhandaICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Prashant KumarICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Upasana KaushikICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Baseer NoorICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Saurabh SharmaIndian Council of Medical Research, New Delhi, India.
Pranay TanwarLaboratory Oncology Unit, Dr. BRA-IRCH, AIIMS New Delhi, India.
Sufian ZaheerDepartment of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Sumita ChaudhryDepartment of Hematology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Prashant PrabhakarDepartment of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Amitabh SinghDepartment of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Bhavika RishiICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.
Aroonima MisraICMR-NICHDR (National Institute of Child Health and Development Research), New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Thiopurines such as 6-mercaptopurine (6-MP) are central to maintenance therapy for pediatric acute lymphoblastic leukemia (ALL), yet their narrow therapeutic index frequently causes dose-limiting myelosuppression in genetically susceptible patients. Variants in Aim: To develop, standardize, and validate a rapid, low-cost tetra-primer ARMS-PCR assay for simultaneous detection of the most clinically relevant variants- Methods: Missense SNPs in Results: In-silico prioritization consistently identified Conclusion: The validated ARMS-PCR assay provides a reliable, rapid, and cost-effective platform for simultaneous

Indexed as

6-mercaptopurineacute lymphoblastic leukemia (ALL)ARMS-PCRgenotype-guided therapyNUDT15 c.415C>TPharmacogeneticsthiopurine toxicityTPMT*3C

Identifiers

PMID41446785
PMCPMC12722899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.